CA Patent

CA2926908C — Amino pyrimidine derivatives

Assigned to Novartis AG · Expires 2021-10-26 · 5y expired

What this patent protects

The present invention describes new amino pyrimidine derivatives of formula (l) and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the amino pyrimidines may be effective in the treatment of autoimmune disorders…

USPTO Abstract

The present invention describes new amino pyrimidine derivatives of formula (l) and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

Drugs covered by this patent

Patent Metadata

Patent number
CA2926908C
Jurisdiction
CA
Classification
—
Expires
2021-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.